CBLL trades 38.7% below Wall Street's consensus target of $25.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CBLL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, CeriBell, Inc. (CBLL) has a Wall Street consensus price target of $25.00, based on estimates from 4 covering analysts. With the stock currently trading at $18.18, this represents a potential upside of +38.7%. The company has a market capitalization of $690M.
Analyst price targets range from a low of $25.00 to a high of $25.00, representing a 0% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CBLL trades at a trailing P/E of -12.5x. Analysts expect EPS to grow -6.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $1.5B | $13.61 | $33.00 | +131.1% | Buy | — | 15 |
LIVNLivaNova PLC | $4.3B | $78.71 | $79.86 | +1.7% | Buy | 18.5x | 14 |
INVAInnoviva, Inc. | $1.7B | $22.67 | $37.00 | +64.5% | Buy | 6.3x | 10 |
ACLSAxcelis Technologies, Inc. | $5.7B | $183.92 | $128.00 | -31.7% | Buy | 48.9x | 12 |
MDTMedtronic plc | $101.8B | $79.27 | $95.80 | +20.7% | Buy | 13.3x | 51 |
ABTAbbott Laboratories | $152.6B | $87.78 | $127.46 | +44.2% | Buy | 16.1x | 41 |
PHGKoninklijke Philips N.V. | $25.7B | $26.98 | — | — | Hold | 17.1x | 22 |
GEGE Aerospace | $371.0B | $355.12 | $380.14 | +6.3% | Buy | 47.4x | 34 |
GEHCGE HealthCare Technologies Inc. | $27.6B | $60.64 | $81.10 | +31.7% | Buy | 12.6x | 18 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying CBLL stock.
The consensus Wall Street price target for CBLL is $25, representing 38.7% upside from the current price of $18.18. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CBLL has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $25 implies 38.7% upside from current levels.
CBLL's current price is $18.18 with a consensus target of $25 (38.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $25 for CBLL, while the most conservative target is $25. The consensus of $25 represents the median expectation. These targets typically reflect 12-month expectations.
CBLL is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CBLL stock forecast based on 4 Wall Street analysts shows a consensus price target of $25, with estimates ranging from $25 (bear case) to $25 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CBLL, with a "Buy" consensus rating and $25 price target (38.7% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CBLL analyst price targets range from $25 to $25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.